Quantitative Proteomics Reveal That Metabolic Improvement Contributes to the Cardioprotective Effect of T89 on Isoproterenol-Induced Cardiac Injury

BackgroundT89, a traditional Chinese medicine, has passed phase II, and is undergoing phase III clinical trials for treatment of ischemic cardiovascular disease by the US FDA. However, the role of T89 on isoproterenol (ISO)-induced cardiac injury is unknown. The present study aimed to explore the ef...

Full description

Bibliographic Details
Main Authors: Xiao-Hong Wei, Xiao Guo, Chun-Shui Pan, Huan Li, Yuan-Chen Cui, Li Yan, Jing-Yu Fan, Jing-Na Deng, Bai-He Hu, Xin Chang, Shu-Ya He, Lu-Lu Yan, Kai Sun, Chuan-She Wang, Jing-Yan Han
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Physiology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphys.2021.653349/full